RxDoctor Payments Data

Cynthia Schackman

Psychiatric/Mental Health · Bemidji, MNNPI 1154419877

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $153 and has fallen 75.0% since, to $38 in 2025.

$371in general payments, 2019–2025

Across 26 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$87
  • Neurocrine Biosciences, Inc.$55
  • Sunovion Pharmaceuticals Inc.$43
  • Eisai Inc.$29
  • E.r. Squibb & Sons, L.L.C.$20
  • Tris Pharma Inc$20
  • plus $117 from 8 others

What the payments were for

  • Food & beverage$371100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$371 in reported general payments places this provider in the 85th percentile of 407 psychiatric/mental health providers in Minnesota.

See all psychiatric/mental health providers in Minnesota

Medicare billing

Part B allowed, 2024
$19,969
Medicare patients
49
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole48$137,452
IngrezzaValbenazine Tosylate13$92,969
RexultiBrexpiprazole42$64,089
Invega SustennaPaliperidone Palmitate11$25,552
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine140$7,969
Lurasidone Hcl15$5,522
Quetiapine Fumarate ErQuetiapine Fumarate14$4,984
Duloxetine Hcl195$4,292
Aripiprazole125$3,429
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine121$2,952
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl22$2,826
Eszopiclone45$2,750
Buspirone Hcl194$2,435
Olanzapine113$1,709
Ziprasidone Hcl16$1,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$15$201,54190 claims
Neurocrine Biosciences, Inc.Ingrezza$55$92,96913 claims
Johnson & JohnsonInvega Sustenna$11$25,55211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 407 psychiatric/mental health providers in Minnesota.

Other psychiatric/mental health in Bemidji

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →